Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
As we enter spring, several companies have refreshed the look of their executive boards – some to strengthen their direction and some out of necessity.